Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022-Growth Driven By Increasing Treatment-Receiving Pool: Ken Research

Hemophilia is a rare disease affecting more than 400,000 people worldwide. Hemophilia A is four times as common as hemophilia B, and more than half of patients with hemophilia A have a severe form of hemophilia. Males have a much higher chance of developing hemophilia because they only receive one copy of the X chromosome from their mother.

Hemophilia A and B Therapeutics Market

The mainstay of treatment for hemophilia is to replace the missing factor VIII or factor IX, produced using plasma-derived or recombinant methods. Some patients develop inhibitors to factor VIII or factor IX treatment and need a bypassing agent, such as factor VIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative market opportunity.

The current marketed products landscape comprises replacement factor therapies, such as recombinant therapies and new long-acting recombinant products. The current pipeline shows strong promise, as it shows a gradual shift from short-acting recombinant factor VIII or factor IX to long-acting recombinant factor VIII, and from factor replacement therapies to non-factor therapies. Nevertheless, significant unmet need remains for products that can avoid the development of inhibitors in patients with hemophilia.

Though late-stage pipeline for treatment of hemophilia seems promising, the main market restraint is likely to be low penetration of new long-acting recombinant therapies in India and China, owing to their high expected prices.

Key topics covered in report

Hemophilia A and B Therapeutics Market Size

Hemophilia A and B Therapeutics Market Share

Hemophilia A and B Therapeutics Market Trends

Hemophilia A and B Therapeutics Market Growth

Hemophilia A and B Therapeutics Market Outlook

Hemophilia A and B Therapeutics Market Analysis

Hemophilia A and B Therapeutics Market Research

Hemophilia A and B Therapeutics Market Revenue

Hemophilia A and B Therapeutics Market Research Report

For more coverage click on the link below:

https://www.kenresearch.com/healthcare/pharmaceuticals/hemophilia-a-b-therapeutics-asia-pacific-markets/64680-91.html

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications

Ankur@kenresearch.com

+91-9015378249

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s